SCHEMBL19344137

SCHEMBL19344137

Nc1ncnn2c([C@@H]3O[C@H](CN4CC(F)(F)C[C@H]4CCN4CCOCC4)[C@@H](O)[C@H]3O)ccc12

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.34
▸ PRMT5 O14744 2/20 0.32
▸ ACVRL1 P37023 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19344138 0.94 POLRMT (0.34) POLRMTPRMT5
SCHEMBL19344161 0.88 PRMT5 (0.37) POLRMTPRMT5
SCHEMBL22435039 0.87 — —
SCHEMBL19344142 0.86 PRMT5 (0.42) POLRMTPRMT5ACVRL1
SCHEMBL19344139 0.85 DOT1L (0.35) POLRMTPRMT5
SCHEMBL23584783 0.84 — —
SCHEMBL19344136 0.83 DOT1L (0.36) POLRMTPRMT5
SCHEMBL19344305 0.82 PRMT5 (0.39) POLRMTPRMT5
SCHEMBL19344162 0.81 POLRMT (0.35) POLRMTPRMT5
SCHEMBL19344170 0.80 POLRMT (0.30) POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed
WO-2017153186-A1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 POLRMT 407/4885PRMT5 1/4885ACVRL1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback